What is ED&D?
The Early Diagnosis and Detection (ED&D) Centre at The Royal Marsden and the Institute of Cancer Research (ICR) relates to discovery and translation of novel early cancer diagnosis, detection and prevention.
ED&D proposes a two-step diagnostic strategy to detect cancer at its earliest, most curable stage. This approach consists of using screening technologies as a first step, identifying individuals who are likely to have higher risk of cancer or more aggressive cancer (using biomarker tests in blood, urine, saliva, etc.), followed by cutting-edge diagnostics such as imaging or liquid biopsy technologies to diagnose cancers. We are one of the leading centres to combine this with use of Artificial Intelligence (AI) for earlier diagnosis, detection, and prevention.
To support our integrated research strategy, our key focus areas are :
- Risk Stratification / Targeted Early Diagnosis
- Molecular Detection / Liquid Biopsy Technologies
- Convergence Science e.g. Point of care tests
- Artificial Intelligence & Computational approaches
- Population Studies: Epidemiology & Behavioural factors
- Delivering patient facing early diagnosis studies locally and nationally
- Driving new innovative models of early diagnosis care, based on our research, through NHS England
How are we different from other early diagnosis and detection centres?
Early Diagnosis and Detection centre will focus on risk stratified early diagnosis. Our expertise will be utilisied to achieve this through cancer genetics as well as our patient community presenting with variety of different conditions. This can help us to develop cutting edge liquid biopsy biomarkers and AI early detection tools.
Our facilities are likely to expand further with the new Oak Cancer Centre based at The Royal Marsden, as we continue to harness future partnerships with key stakeholders.
Please note this diagram should not be used or replicated without permission.